


Supports the Resilience of the Body!

Stein Ulve CEO and Founder Eevia Health Plc Aktiespararna, March 15, 2023

Cellular Health and Recycling


- Human body has 30 trillion cells (> 200 different cell types)
- All cells are replaced every 7-10 years
 - Exception neuronal and eye lens cells



Cell death is a vital biological process! Healthy cells = Healthy body



AutophagyAuto = selfPhagos = eat or consume




Dysfunctional cell autophagy leads to waste accumulation

Cellular health

- Waste accumulation and dysfunctional recycling
- Reactive oxygen species (ROS)
- Gene mutations
- Inflammation



Cellular dysfunction



AMD AGE-RELATED MACULAR DEGENERATION A GLOBAL HEALTH PROBLEM




RETINARI OBJECTIVES:

Reduce AMD cases causing (legal) blindness **by 25 %** Reduce the economic burden of AMD in the EU by **25 B€**


≻ By **2040**



A HEALTHY EYE



B AMD EYE





Prevent vs. Repair

PROBLEM


AMD is currently addressed only in the late stage, by expensive (500€–2000€ per shot) and painful drug injection treatments to the eye.



SOLUTION

Prophylactic dietary supplement intervention on AMD development already **before onset or in the early stage**, years before injections are even required.






Retinari[™] improves the **underlying** conditions behind AMD, the agerelated **impairment of autophagy** and retinal **cytoprotective** capacity.



A unique value proposition



AMD animal studies^{*} show substantial beneficial effects from Retinari in **vision** and **tissue** level.

Pinosylvin Extract Retinari[™] Sustains Electrophysiological Function, Prevents Thinning of Retina, and Enhances Cellular Response to Oxidative Stress in NFE2L2 Knockout Mice Oxidative Medicine and Cellular Longevity December 2021(Part B):1-16 DOI:10.1155/2021/8028427

Treatment with Pinosylvin extract Retinari[™] sustains electrophysiological function and prevents thinning of retina in AMD mice.

International Journal of Molecular Sciences. 2020. 21.

A major market opportunity

Retinari[™] will target a **3.2 B€ AMD supplement market** predicted to grow at **7–9** % **CAGR** for the next 30 years due to aging populations.

2025 2040 SERVICEABLE MARKET SIZE TARGET MARKET SHARE MARKET SIZE TARGET MARKET SHARE 55 M 3.2 M 115 M 115 M 11.5 M

A 10 % market share by 2040 would translate into 1.1 B€ revenue

Source data: Persistence Market Research, 2016, EURETINA Report (European society of Retina Specialists), August 2017 and https://www.who.int/blindness/en/.

Eevia targets health challenges with bioactive extracts from arctic plant material.



Organic, wild-harvested berries, bark, and mushrooms. Products address important global health challenges -> Cellular recycling



Sustainability and environmental responsibility Operating a state-of-the-art green chemistry production facility in Finland.

Net revenues 2022: € 5,9 M

EBITDA 2022 € 0,02 M Employees: 28



Arctic renewable high-potency organic raw materials



HEALTH


Demand for natural extracts

- Increased health awareness drives demand for prophylactic health products
- Geopolitical tensions cause Western brand owners to seek Western supply
- Demographic shifts in the global population and an increasing average life expectancy drive the need for cellular health supplementation



Plant extracts market

- Global nutraceuticals market estimated @ USD 241B in
 2019 and projected to be USD 373 B in 2025 (CAGR 7,5%)*
- Global Plant extract market estimated @ USD 24 B in
 2019 and projected to be USD 59 B 2025 (CAGR 16,5%)**






59.4

* Source: PMMI BIM Report 2021 ** Source: AlliedMarketResearch, Plant Extracts Market, 2019

Markets & Distribution

- Eevia's key markets are USA, Europe, and Australia
- Carefully selected high-quality distributors provide a wide and deep market access
- Potential new geographical market areas in Asia





Product portfolio

Abundant resources	Ingredient products	Market size
WILD BERRIES	Feno-Myrtillus® Feno-Vitis® Feno-Sambucus®	EUR 1 Billion +*
WILD ARCTIC WOOD	Fenoprolic®	EUR 0,5 Billion +**
WILD ARCTIC FUNGI	Feno-Chaga®	EUR 160 Million +***

<section-header>







LUMENE THE FREEZE NORT CEEDEN Kentycher Porse



* Source: World Health Organization ** Source: Mintel GNPD; Zion Market Research 2018 *** Source: Management estimates

Autophagy from berry anthocyanins

Recent study showed that bilberry anthocyanins induced autophagy by activating AMPK-mTOR pathway and alleviating oxidative stress caused by aging in rats (Li et al 2019, J Agric Food Chem)

Cherry anthocyanins have been proven to increase autophagy in HepG2 cells

Cherry anthocyanins (CACN) activates autophagy in HepG2 cells. OA=oleic acid, oxidative stressor; 3-MA= autophagy inhibitor Chu et al 2019, Oxidative Medicine and Cellular Longevity

-	OS + control			
	OS + Anthocyanin			
	OS + autophagy inhibitor 3-MA			
ce or	ells.	Cell amount	Autophagy marker LC3B	Autophagy marker ATG7

HEALTH

ANTHOCYANINS MAY BE A POTENTIAL WAY TO INCREASE CELLULAR RECYCLING

Competitive landscape for berry extracts

- Depending on the market and product line, Eevia has distinct competitors for each category
- For bilberry extracts, BGC, Indena and Linnea
- For elderberry extract, Artemis International
- For lingonberry extract, Iprona and BGG

	indena	B C BGG	Others	
Brand awareness	۷			(√)
Quality	V			٧
Cost		(√)	(√)	٧
Organic				V
Focus				V
Supply chain	V	٧		۷

OCT

Eevia as a unique supplier

- Organic certification from the Nordic
- Manufacturing close to harvesting sites results in authetic and sustainable products
- Unrivaled quality and high potency
- Beneficial composition, anthocyanin profile, nutritional profile, possibilities for differentiation



Management team



Petri Lackman - Chief Technology Officer



Harri Salo – Chief Manufacturing Officer



Stein Ulve - Chief Executive Officer



Matleena Kotila – Commercial Manager




Share price development

Eevia Health share price at Spotlight Stockmarket



Share price: SEK 1,55 Market Cap: SEK 47 millioner **P/S-ratio**: 0,67 **Equity research:** Analyst Group https://analystgroup.se/bolag/ eevia-health/


Net revenue development 2017 - 2022



HEALTH

Revenues Trading


EBITDA development Q1-20 – Q4-22



HEALTH

Production performance development

Product Equivalent Output per batch (Campaign Averages)



Key Milestones reached in Q1 2023: First-ever campaign(s) completed with over 250 Product Equivalent Output on average.

Summary of Eevia value proposition

- Unique position with organic highquality extracts from the arctic
- Strong supply chain in key raw material markets.
- Differentiation options as value drivers
- Huge market- and growth potential in key indications such as cellular health



THANK YOU FOR YOUR ATTENTION!

STEIN ULVE Chief Executive officer EEVIA HEALTH OYJ

Tel: +358 400 22 5967



HEALTH

www.eeviahealth.com